Thursday, February 16, 2023 5:29:30 PM
Recent EOLS News
- Evolus to Participate in Stifel 2024 Healthcare Conference • Business Wire • 11/01/2024 12:00:00 PM
- Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation • Business Wire • 10/31/2024 06:02:00 PM
- Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers • Business Wire • 10/29/2024 12:00:00 PM
- Evolus to Report Third Quarter Financial Results on November 6, 2024 • Business Wire • 10/23/2024 12:00:00 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 10/12/2024 02:53:00 AM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/28/2024 01:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/07/2024 01:45:54 AM
- Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 • Business Wire • 09/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:14:51 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/09/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 09:00:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:12:11 PM
- Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance • Business Wire • 07/31/2024 08:05:00 PM
- Evolus to Hold Investor Day on September 12, 2024 • Business Wire • 07/31/2024 12:00:00 PM
- Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia • Business Wire • 07/30/2024 12:00:00 PM
- Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference • Business Wire • 07/25/2024 12:00:00 PM
- Evolus to Report Second Quarter Financial Results on July 31, 2024 • Business Wire • 07/17/2024 12:00:00 PM
- Evolus Announces Appointment of Albert G. White III to Board of Directors • Business Wire • 07/01/2024 12:00:00 PM
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products • Business Wire • 06/24/2024 12:00:00 PM
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain • Business Wire • 06/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:05:21 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/07/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:01:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 09:45:29 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM